
Ralaniten triacetate
CAS No. 1637573-04-6
Ralaniten triacetate( —— )
Catalog No. M34834 CAS No. 1637573-04-6
Ralaniten triacetate (EPI-506), a precursor of Ralaniten, is a first-of-its-kind, orally active androgen receptor N-terminal structural domain (AR-NTD) inhibitor with anticancer activity and can be used to study prostate and breast cancer.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 251 | Get Quote |
![]() ![]() |
5MG | 392 | Get Quote |
![]() ![]() |
10MG | 655 | Get Quote |
![]() ![]() |
25MG | 1371 | Get Quote |
![]() ![]() |
50MG | 1822 | Get Quote |
![]() ![]() |
100MG | 2250 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameRalaniten triacetate
-
NoteResearch use only, not for human use.
-
Brief DescriptionRalaniten triacetate (EPI-506), a precursor of Ralaniten, is a first-of-its-kind, orally active androgen receptor N-terminal structural domain (AR-NTD) inhibitor with anticancer activity and can be used to study prostate and breast cancer.
-
DescriptionRalaniten triacetate (EPI-506), the pro-agent of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7.
-
In VitroRalaniten triacetate (EPI-506) targets the N-terminal domain of the androgen receptor (AR), and is used for metastatic castration-resistant prostate cancer (mCRPC) research. EPI-506 is a first-in-class, highly-specific small molecule that binds to a novel target on the AR, the N-terminal domain (NTD) and directly inhibits AR transcriptional activity by blocking the interaction of the AR with transcriptional proteins
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetAndrogen Receptor (AR)
-
RecptorAndrogen Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1637573-04-6
-
Formula Weight521
-
Molecular FormulaC27H33ClO8
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (191.94 mM; Ultrasonic )
-
SMILESCC(=O)OC[C@H](COc1ccc(cc1)C(C)(C)c1ccc(OC[C@@H](CCl)OC(C)=O)cc1)OC(C)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Obst JK, et al. Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. ACS Pharmacol Transl Sci. 2019;2(6):453-467. Published 2019 Sep 26.?
molnova catalog



related products
-
JNJ63576253
JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
-
17-Methyltestosteron...
17α-Methyltestosterone has similar binding affinity to AR and similar androgenic and anabolic activities as testosterone.
-
Testosterone
Testosterone is a steroid hormone from the androgen group and is found in mammals, reptiles, birds, and other vertebrates.